Insider · CIK 0001575951

Ratliff John D

Reports to the SEC for 2 companies · DURHAM, NC

sec.gov

Transactions

Companies

Filings

CIK

0001575951

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-04-03	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+2,424 sh	—	—	18,025
2019-04-03	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−1,084 sh	$156.68	−$170K	16,941
2019-04-03	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−2,424 sh	—	—	19,787
2019-02-12	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+1,463 sh	—	—	16,255
2019-02-12	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−654 sh	$146.59	−$95.9K	15,601
2019-02-12	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−1,463 sh	—	—	16,911
2019-02-12	LHLABCORP HOLDINGS INC. · Restricted Stock UnitA Award	CEO, Covance Drug Development	AAward	+5,300 sh	—	—	22,211
2019-02-12	LHLABCORP HOLDINGS INC. · Non-qualified Stock OptionsA Award	CEO, Covance Drug Development	AAward	+21.8K sh	—	—	21,800
2019-02-11	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+6,100 sh	—	—	16,765
2019-02-11	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−1,973 sh	$144.29	−$285K	14,792
2019-02-11	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−6,100 sh	—	—	18,374
2019-02-07	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+1,863 sh	—	—	11,261
2019-02-07	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−556 sh	$147.46	−$82K	10,665
2019-02-07	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−1,863 sh	—	—	24,474
2018-04-03	LHLABCORP HOLDINGS INC. · Restricted Stock UnitA Award	CEO, Covance Drug Development	AAward	+12.1K sh	—	—	26,337
2018-02-12	LHLABCORP HOLDINGS INC. · Non-qualified Stock OptionsA Award	CEO, Covance Drug Development	AAward	+17.1K sh	—	—	17,100
2018-02-12	LHLABCORP HOLDINGS INC. · Restricted Stock UnitA Award	CEO, Covance Drug Development	AAward	+4,390 sh	—	—	14,217
2018-02-09	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+6,100 sh	—	—	11,530
2018-02-09	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−2,132 sh	$168.08	−$358K	9,398
2018-02-09	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−6,100 sh	—	—	9,827
2018-02-07	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+1,863 sh	—	—	5,990
2018-02-07	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−560 sh	$169.66	−$95K	5,430
2018-02-07	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−1,863 sh	—	—	15,927
2017-02-09	LHLABCORP HOLDINGS INC.M Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	+6,100 sh	—	—	6,140
2017-02-09	LHLABCORP HOLDINGS INC.F Tax Payment	CEO, Covance Drug Development	FTax Payment	−2,013 sh	$133.83	−$269K	4,127
2017-02-09	LHLABCORP HOLDINGS INC. · Restricted Stock UnitM Exercise/Conversion	CEO, Covance Drug Development	MExercise/Conversion	−6,100 sh	—	—	17,790
2017-02-07	LHLABCORP HOLDINGS INC. · Restricted Stock UnitA Award	CEO, Covance Drug Development	AAward	+5,590 sh	—	—	23,890
2017-02-07	LHLABCORP HOLDINGS INC. · Non-qualified Stock OptionsA Award	CEO, Covance Drug Development	AAward	+21.3K sh	—	—	21,300
2016-10-03	LHLABCORP HOLDINGS INC. · Restricted Stock UnitA Award	CEO, Covance Drug Development	AAward	+18.3K sh	—	—	18,300
2013-11-18	IQVIQVIA HOLDINGS INC.X Exercise of In-Money	President and COO	XExercise of In-Money	+75K sh	$6.61	+$496K	75,000
2013-11-18	IQVIQVIA HOLDINGS INC.X Exercise of In-Money	President and COO	XExercise of In-Money	+40K sh	$5.76	+$230K	115,000
2013-11-18	IQVIQVIA HOLDINGS INC.S Sale	President and COO	SSale	−115K sh	$42.55	−$4.89M	0
2013-11-18	IQVIQVIA HOLDINGS INC.S Sale	President and COO	SSale	−97.1K sh	$42.55	−$4.13M	0
2013-11-18	IQVIQVIA HOLDINGS INC. · Employee Stock Option (Right to Buy)X Exercise of In-Money	President and COO	XExercise of In-Money	−75K sh	—	—	0
2013-11-18	IQVIQVIA HOLDINGS INC. · Employee Stock Option (Right to Buy)X Exercise of In-Money	President and COO	XExercise of In-Money	−40K sh	—	—	0
2013-05-08	IQVIQVIA HOLDINGS INC. · Employee Stock Option (Right to Buy)A Award	President and COO	AAward	+50K sh	—	—	50,000
2013-05-08	IQVIQVIA HOLDINGS INC. · Employee Stock Option (Right to Buy)A Award	President and COO	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Apr 54
Ratliff John D0001127602-19-014865
SEC(opens sec.gov)
Feb 144
Ratliff John D0001127602-19-005984
SEC(opens sec.gov)
Feb 134
Ratliff John D0001127602-19-005556
SEC(opens sec.gov)
Feb 114
Ratliff John D0001127602-19-005195
SEC(opens sec.gov)
Apr 54
Ratliff John D0001127602-18-014165
SEC(opens sec.gov)
Feb 144
Ratliff John D0001127602-18-005993
SEC(opens sec.gov)
Feb 134
Ratliff John D0001127602-18-005415
SEC(opens sec.gov)

Companies

Address

C/O QUINTILES TRANSNATIONAL HOLDINGS INC 4820 EMPEROR BLVD.

DURHAM, NC, 27703